Evidation Study Validates Key Outcomes for Omada Diabetes Program
Decentralized Clinical Trial Provides Additional Evidence of Significant Clinical Outcomes
San Francisco, CA (September 2, 2020) — Continuing the company’s commitment to rigorous measurement of its digital care programs, Omada Health today announced the results of a clinical study run in collaboration with Evidation Health. The study demonstrated the Omada for Diabetes Program participants achieved meaningful outcomes four months after beginning the program, including:
- Reducing average Hemoglobin A1c by 0.8 percent for all study participants, including a 1.4 percent average reduction for individuals with starting values at or above 9 percent;
- An average decrease of 39 points in total cholesterol for people with high cholesterol;
- An additional 11 percent of study participants adhering to their medication regimen; and
- Meaningful decreases in diabetes distress, a measure of feelings of stress and anxiety associated with the burden of diabetes.
“When choosing a digital diabetes solution for their population, decision-makers deserve real, verified clinical results,” said Omada Co-Founder and CEO Sean Duffy. “From its inception, Omada has prioritized rigorous evaluation of our programs. Today’s results show again that Omada’s programs deliver real-world outcomes that drive real differences in people’s lives, and real clinical results.”
The study took place from November 2019 through July 2020, meaning participants maintained engagement, and achieved results, throughout the COVID-19 public health emergency. The study was conducted using Evidation’s Achievement platform and population. Hemoglobin A1c was captured through a combination of laboratory measurements and at-home test kits supplied to study participants. The study population included 195 participants with a diagnosis of Type 2 Diabetes, and an average starting baseline A1c of 8.93%. Full study results will be published later this year.
“Our goal at Omada is to change the shape of healthcare -- today, and for the future,” said Cynthia Castro Sweet, PhD, Omada’s Director of Clinical Research who supervised the study. “That requires clean, rigorous evidence -- which is exactly why we partnered with Evidation to run this study and provide hard data of our program’s ability to improve participants’ control of their diabetes.”
“These results demonstrate the power of the Omada Diabetes Program to meaningfully improve quantitative and qualitative measures of health in individuals with Type 2 Diabetes, including in those at higher risk of diabetes-related complications,” said Jessie Juusola, Executive Director of Digital Health Outcomes at Evidation Health. “Evidation is proud to enable rapid, reliable, and decentralized evidence generation for this critical intervention, especially during COVID-19.”
